- Risk reduction of myocardial infarction, unstable angina, and/or coronary revascularization procedures in individuals without symptomatic cardiovascular disease, average to moderately elevated Total-C and LDL-C, and below average HDL-C
- Slowing the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower Total-C and LDL-C to target levels
- Hyperlipidemia as an adjunct to diet for the reduction of elevated Total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson types IIa and IIb, see Table VI) when the response to diet restricted in saturated fat and cholesterol and to other non-pharmacological measures alone has been inadequate
- Primary hyperlipidemia and mixed dyslipidemia as an adjunct to diet to reduce elevated total-C (cholesterol), LDL-C, ApoB, nonHDL-C,and TG levels and to increase HDL-C
- Hypertriglyceridemia as an adjunct to diet
- Homozygous familial hypercholesterolemia to reduce LDL-C, total-C,and ApoB
- Slowing the progression of atherosclerosis as part of a treatment strategy to lower total-C and LDL-C as an adjunct to diet
- Primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet.
- Pediatric patients 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total-C, LDL-C and ApoB after failing an adequate trial of diet therapy
- Risk reduction of MI, stroke, and arterial revascularization procedures in patients without clinically evident CHD, but with multiple risk factors
- Age ≥ 50 years old in men and age ≥ 60 years old in women
- hsCRP ≥ 2 mg/L
- Presence of one additional cardiovascular disease risk factor such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease
- Primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia to reduce elevated total-C, LDL-C, ApoB, TG and nonHDL-C and to increase HDL-C
- Homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments to reduce elevated Total C and LDL-C
- Patients with primary hyperlipidemia or mixed dyslipidemia an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low density lipoprotein (LDL), apolipoprotein B (Apo B), triglycerides (TG), and to increase high density lipoprotein (HDL).